EU releases AI Act transparency guidelines, impacting healthcare AI developers

The European Commission published new guidelines on Monday to help providers and deployers of AI systems meet the transparency obligations set out in the EU AI Act.

The guidance includes examples of situations where the transparency requirements may not apply, clarifying the scope of the rules.

Although the document does not target any specific sector, companies that incorporate AI components into medical products will need to assess how the rules affect their development and marketing practices.

The move reflects the EU’s broader effort to ensure responsible AI use and could influence compliance strategies for pharma firms that rely on AI for drug discovery, diagnostics, or patient monitoring.